Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Systemic immune-inflammation index predicts prognosis of sequential therapy with sorafenib and regorafenib in hepatocellular carcinoma ; volume:21 ; number:1 ; day:18 ; month:5 ; year:2021 ; pages:1-8 ; date:12.2021
BMC cancer ; 21, Heft 1 (18.5.2021), 1-8, 12.2021
- Creator
-
Hong, Young Mi
Yoon, K. T.
Cho, Mong
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12885-021-08124-9
- URN
-
urn:nbn:de:101:1-2021091719544471028433
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:37 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Hong, Young Mi
- Yoon, K. T.
- Cho, Mong
- SpringerLink (Online service)
Other Objects (12)
Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines
A Practical and Efficient Method for the Synthesis of Sorafenib and Regorafenib
Sorafenib versus lenvatinib-based sequential systemic therapy for advanced hepatocellular carcinoma: a real-world analysis
Real-world systemic sequential therapy with regorafenib for recurrent hepatocellular carcinoma: analysis of 93 cases from a single center
Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
High PPT1 expression predicts poor clinical outcome and PPT1 inhibitor DC661 enhances sorafenib sensitivity in hepatocellular carcinoma
Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial
Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial
Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study
Comparative response of nine hepatoma cell lines to the four tyrosine kinase inhibitors, sorafenib, lenvatinib, regorafenib and cabozantinib
Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines
A Practical and Efficient Method for the Synthesis of Sorafenib and Regorafenib
Sorafenib versus lenvatinib-based sequential systemic therapy for advanced hepatocellular carcinoma: a real-world analysis
Real-world systemic sequential therapy with regorafenib for recurrent hepatocellular carcinoma: analysis of 93 cases from a single center
Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
High PPT1 expression predicts poor clinical outcome and PPT1 inhibitor DC661 enhances sorafenib sensitivity in hepatocellular carcinoma
Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial
Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial
Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study
Comparative response of nine hepatoma cell lines to the four tyrosine kinase inhibitors, sorafenib, lenvatinib, regorafenib and cabozantinib
Antagonism of Sorafenib and Regorafenib actions by platelet factors in hepatocellular carcinoma cell lines
A Practical and Efficient Method for the Synthesis of Sorafenib and Regorafenib
Sorafenib versus lenvatinib-based sequential systemic therapy for advanced hepatocellular carcinoma: a real-world analysis
Real-world systemic sequential therapy with regorafenib for recurrent hepatocellular carcinoma: analysis of 93 cases from a single center
Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma
Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
High PPT1 expression predicts poor clinical outcome and PPT1 inhibitor DC661 enhances sorafenib sensitivity in hepatocellular carcinoma
Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial
Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial
Novel FLT3/AURK multikinase inhibitor is efficacious against sorafenib-refractory and sorafenib-resistant hepatocellular carcinoma
Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study